Research
Oppenheimer Initiates Inhibikase Therapeutics at Outperform
Inhibikase Therapeutics (IKT) has an average rating of buy and mean price target of $5.88, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$IKT
